title: [The efficacy and safety of nibentan for pharmacological cardioversion in patients with persistent atrial fibrillation and flutter: the role of dose limitation and magnesium sulfate administration].
abstract: The aim of the study was to evaluate the influence of magnesium sulfate on the efficacy and safety of pharmacological cardioversion with nibentan (NB) in doses up to 0,125 mg/kg in patients with persistent atrial fibrillation (AF) and flutter (AFL). Calculated dose of NB was 0.125 mg/kg. It was administered as 2 bolus injections (0.0625 mg/kg each) performed with the interval of 15 minutes. The study included 64 patients (pts) (45 male, age 54+/-9,9 years) with persistent AF (n=56) and AFL (n=8) with median arrhythmia duration 6,7+/-6,8 months (8 days to 36 months). Pts were divided into two groups. In the first (I) group NB was used without preliminary magnesium sulfate administration, in the second group (II) magnesium sulfate was injected in a dose of 50 mg/kg, followed by 0.83 mg/kg/min infusion before NB administration. There was no difference between groups in conversion rates of atrial arrhythmias: 74% and 69%, in groups I and II, respectively (p>0.4). Mean effective dose of NB was the same in investigated groups - 0.09 mg/kg. Administration of initial dose of NB (0.0625 mg/kg) converted AF/AFL to sinus rhythm within 15-min interval in 29.7% of patients. Efficacy of full dose of NB (0.125 mg/kg) was 100% in AFL, 68% in AF. No side effects were registered after initial injection of 0.0625 mg/kg. After administration of 2 boluses (0.125 mg/kg) "torsade de pointes" developed in 2 pts (3%). Magnesium sulfate administration had no influence on NB efficacy and rate of its proarrhythmic events. Limitation of NB total dose to <or= 0.125 mg/kg divided into 2 bolus injections does not lead to loss of antiarrhythmic efficacy and makes its administration more safe.
authors.forename: I N
authors.initials: IN
authors.lastname: Bregvadze
authors.forename: E B
authors.initials: EB
authors.lastname: Maĭkov
authors.forename: O A
authors.initials: OA
authors.lastname: Bil'dinov
authors.forename: T L
authors.initials: TL
authors.lastname: Kratskina
authors.forename: Iu L
authors.initials: IuL
authors.lastname: Klimenko
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Smirnova
authors.forename: S F
authors.initials: SF
authors.lastname: Sokolov
authors.forename: S P
authors.initials: SP
authors.lastname: Golitsyn
authors.forename: L V
authors.initials: LV
authors.lastname: Rozenshtraukh
authors.forename: E I
authors.initials: EI
authors.lastname: Chazov
mesh_terms: D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy*; D001282:Atrial Flutter / Q000175:diagnosis / Q000188:drug therapy*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008278:Magnesium Sulfate / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D016171:Torsades de Pointes / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D001549:Benzamides; D008278:Magnesium Sulfate; C105049:nibentan